• Менеджмент наследственных нарушений свертываемости крови во время беременности

Менеджмент наследственных нарушений свертываемости крови во время беременности

HEALTH OF WOMAN. 2017.5(121):102–127; doi 10.1111/1471-0528.14592

Pavord S, Rayment R, Madan B, Cumming T, Lester W, Chalmers E, Myers B, Maybury H, Tower C, Kadir R
Руководство № 71 (совместно с UKHCDO)
Апрель 2017 года
Green-top Guideline No. 71. BJOG 2017; DOI: 10.1111/1471-0528.14592.
Сокращенный вариант


1. Bowen DJ. Haemophilia A and haemophilia B: molecular insights. Mol Pathol 2002;55:127–44. https://doi.org/10.1136/mp.55.2.127; https://doi.org/10.1136/mp.55.1.1; PMid:11950963 PMCid:PMC1187163

2. Wacey AI, Tuddenham EG. Mutation databases on the Web. J Med Genet 1998;35:529–33. https://doi.org/10.1136/jmg.35.7.529

3. De Brasi C, El-Maarri O, Perry DJ, Oldenburg J, Pezeshkpoor B, Goodeve A. Genetic testing in bleeding disorders. Haemophilia 2014;20 Suppl 4:54–8. https://doi.org/10.1111/hae.12409; PMid:24762276 PMCid:PMC4274362

4. Kasper CK, Lin JC. Prevalence of sporadic and familial haemophilia. Haemophilia 2007;13:90–2. https://doi.org/10.1111/j.1365-2516.2006.01397.x; PMid:17212731

5. Richards M, Williams M, Chalmers E, Liesner R, Collins P, Vidler V, et al. A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol 2010;149:498–507. https://doi.org/10.1111/j.1365-2141.2010.08139.x; PMid:20230411

6. Miesbach W, Alesci S, Geisen C, Oldenburg J. Association between phenotype and genotype in carriers of haemophilia A. Haemophilia 2011; 17: 246–51. https://doi.org/10.1111/j.1365-2516.2010.02426.x; PMid:21118332

7. Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010;8:1256–65. https://doi.org/10.1111/j.1538-7836.2010.03823.x; PMid:20345722

8. Plug I, Mauser-Bunschoten EP, Brocker-Vriends AH, van Amstel HK, van der Bom JG, van Diemen-Homan JE, et al. Bleeding in carriers of hemophilia. Blood 2006;108:52–6. https://doi.org/10.1182/blood-2005-09-3879; PMid:16551972

9. Renault NK, Dyack S, Dobson MJ, Costa T, Lam WL, Greer WL. Heritable skewed X-chromosome inactivation leads to haemophilia A expression in heterozygous females. Eur J Hum Genet 2007;15:628–37. https://doi.org/10.1038/sj.ejhg.5201799; PMid:17342157

10. Orstavik KH, Scheibel E, Ingerslev J, Schwartz M. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B. Thromb Haemost 2000;83:433–7. PMid:10744150

11. Chi C, Lee CA, Shiltagh N, Khan A, Pollard D, Kadir RA. Pregnancy in carriers of haemophilia. Haemophilia 2008;14: 56–64. PMid:17941828

12. Sachs BP, Acker D, Tuomala R, Brown E. The incidence of symptomatic intracranial hemorrhage in term appropriate-for- gestation-age infants. Clin Pediatr (Phila) 1987;26:355–8. https://doi.org/10.1177/000992288702600706; PMid:3595041

13. Hanigan WC, Powell FC, Miller TC, Wright RM. Symptomatic intracranial haemorrhage in full-term infants. Childs Nerv Syst 1995;11:698–707. https://doi.org/10.1007/BF00262235; PMid:8750952

14. Towner D, Castro MA, Eby-Wilkens E, Gilbert WM. Effect of mode of delivery in nulliparous women on neonatal intracranial injury. N Engl J Med 1999; 341:1709–14. https://doi.org/10.1056/NEJM199912023412301; PMid:10580069

15. Hughes CA, Harley EH, Milmoe G, Bala R, Martorella A. Birth trauma in the head and neck. Arch Otolaryngol Head Neck Surg 1999;125:193–9. https://doi.org/10.1001/archotol.125.2.193; PMid:10037286

16. Mosavat SA, Zamani M. The incidence of birth trauma among live born term neonates at a referral hospital in Rafsanjan, Iran. J Matern Fetal Neonatal Med 2008;21:337–9. https://doi.org/10.1080/14767050801927921; PMid:18446662

17. LjungRC, SjorinE. Origino fmutationinsporadiccasesof haemophilia A. Br J Haematol 1999;106:870–4. https://doi.org/10.1046/j.1365-2141.1999.01631.x

18. Yoffe G, Buchanan GR. Intracranial hemorrhage in newborn and young infants with hemophilia. J Pediatr 1988;113:333–6. https://doi.org/10.1016/S0022-3476(88)80277-4

19. Klinge J, Auberger K, Auerswald G, Brackmann HH, Mauz-Korholz C, Kreuz W. Prevalence and outcome of intracranial haemorrhage in haemophiliacs a survey of the paediatric group of the German Society of Thrombosis and Haemostasis (GTH). Eur J Pediatr 1999;158 Suppl 3:S162–5.  https://doi.org/10.1007/PL00014346; PMid:10650860

20. Revel-Vilk S, Golomb MR, Achonu C, Stain AM, Armstrong D, Barnes MA, et al. Effect of intracranial bleeds on the health and quality of life of boys with hemophilia. J Pediatr 2004;144:490–5. https://doi.org/10.1016/j.jpeds.2003.12.016; PMid:15069398

21. MacLean PE, Fijnvandraat K, Beijlevelt M, Peters M. The impact of unaware carriership on the clinical presentation of haemophilia. Haemophilia 2004;10:560–4. https://doi.org/10.1111/j.1365-2516.2004.00955.x; PMid:15357784

22. Tarantino MD, Gupta SL, Brusky RM. The incidence and outcome of intracranial haemorrhage in newborns with haemophilia: analysis of the Nationwide Inpatient Sample database. Haemophilia 2007;13:380–2. https://doi.org/10.1111/j.1365-2516.2007.01492.x; PMid:17610551

23. Kulkarni R, Soucie JM, Lusher J, Presley R, Shapiro A, Gill J, et al.; Haemophilia Treatment Center Network Investigation. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention’s (CDC) Universal Data Collection (UDC) project. Haemophilia 2009;15:1281–90. https://doi.org/10.1111/j.1365-2516.2009.02074.x; PMid:19637999

24. Kenet G, Chan AKC, Soucie JM, Kulkarni R. Bleeding disorders in neonates. Haemophilia 2010;16 Suppl 5:168–75. https://doi.org/10.1111/j.1365-2516.2010.02316.x; PMid:20590877

25. Richards M, Lavigne Lissalde G, Combescure C, Batorova A, Dolan G, Fischer K, et al.; European Haemophilia Treatment and Standardization Board. Neonatal bleeding in haemophilia: a European cohort study. Br J Haematol 2012;156:374–82. https://doi.org/10.1111/j.1365-2141.2011.08967.x; PMid:22146054

26. Davies J, Kadir RA. Mode of delivery and cranial bleeding in newborns with haemophilia: a systematic review and meta- analysis of the literature. Haemophilia 2016;22:32–8.  https://doi.org/10.1111/hae.12726; PMid:25990680

27. Chalmers E, Williams M, Brennand J, Liesner R, Collins P, Richards M; Paediatric Working Party of United Kingdom Haemophilia Doctors’ Organization. Guideline on the management of haemophilia in the fetus and neonate. Br J Haematol 2011; 154: 208–15. https://doi.org/10.1111/j.1365-2141.2010.08545.x; PMid:21554256

28. Kulkarni R, Ponder KP, James AH, Soucie JM, Koerper M, Hoots WK, et al. Unresolved issues in diagnosis and management of inherited bleeding disorders in the perinatal period: a White Paper of the Perinatal Task Force of the Medical and Scientific Advisory Council of the National Hemophilia Foundation, USA. Haemophilia 2006;12:205–11. https://doi.org/10.1111/j.1365-2516.2006.01277.x; PMid:16643202

29. Maternal obesity and maternal health [www.noo.org.uk/NOO_about_ obesity/maternal_obesity/maternalhealth]. Accessed 2015 Oct 7.

30. NHS England. Clinical Commissioning Policy: Pre-implantation Genetic Diagnosis (PGD). Leeds: NHS England, 2014 [www. england. nhs.uk/ wp-content/ uploads/ 2014/04/ e01-med-gen-0414.pdf]. Accessed 2016 Jun 15.

31. Fernandez RM, Pecina A, Sanchez B, Lozano-Arana MD, Garcіa-Lozano JC, Perez-Garrido R, et al. Experience of preimplantation genetic diagnosis for hemophilia at the University Hospital Virgen Del Roc эo in Spain: technical and clinical overview. Biomed Res Int 2015;2015:406096.

32. Kadir RA, Sabin CA, Goldman E, Pollard D, Economides DL, Lee CA. Reproductive choices of women in families with haemophilia. Haemophilia 2000;6:33–40. https://doi.org/10.1046/j.1365-2516.2000.00353.x; PMid:10632739

33. Tengborn L, Blomback M, Berntorp E.Tranexamicacid anold drug still going strong and making a revival. Thromb Res 2015;135: 231–42. https://doi.org/10.1016/j.thromres.2014.11.012; PMid:25559460

34. Mannucci PM, Canciani MT, Rota L, Donovan BS. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with haemophilia A and von Willebrand’s disease. Brit J Haematol 1981; 47: 283–93. https://doi.org/10.1111/j.1365-2141.1981.tb02789.x

35. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003;1:682–9. https://doi.org/10.1046/j.1538-7836.2003.00190.x

36. Leissinger C, Carcao M, Gill JC, Journeycake J, Singleton T, Valentino L. Desmopressin (DDAVP) in the management of patients with congenital bleeding disorders. Haemophilia 2014; 20: 158–67. https://doi.org/10.1111/hae.12254; PMid:23937614

37. Trigg DE, Stergiotou I, Peitsidis P, Kadir RA. A systematic review: The use of desmopressin for treatment and prophylaxis of bleeding disorders in pregnancy. Haemophilia 2012;18:25–33. https://doi.org/10.1111/j.1365-2516.2011.02573.x; PMid:21624012

38. Street AM, Ljung R, Lavery SA. Management of carriers and babies with haemophilia. Haemophilia 2008;14 Suppl 3:181–7. https://doi.org/10.1111/j.1365-2516.2008.01721.x; PMid:18510540

39. Abdul-Kadir R, Davies J, Halimeh S, Chi C. Advances in pregnancy  management in carriers of hemophilia. J Appl Hematol 2013;4:125. https://doi.org/10.4103/1658-5127.127894

40. Mannucci PM. Use of desmopressin (DDAVP) during early  pregnancy in factor VIII-deficient women. Blood 2005; 105: 3382. https://doi.org/10.1182/blood-2004-11-4472; PMid:15802549

41. Kno€fler R, Koscielny J, Tauer JT, Huhn B, Gneuss A, Kuhlisch E, et al. Desmopressin testing in haemophilia A patients and carriers: results of a multi centre survey. Hamostaseologie 2012;32:271–5. https://doi.org/10.5482/HAMO-12-06-0012; PMid:22940861

42. Dunkley SM, Russell SJ, Rowell JA, Barnes CD, Baker RI, Sarson MI, et al.; Australian Haemophilia Centre Directors’ Organisation. A consensus statement on the management of pregnancy and delivery in women who are carriers of or have bleeding disorders. Med J Aust  2009;191:460–3. PMid:19835544

43. Grootscholten K, Kok M, Oei SG, Mol BW, van der Post JA.  External cephalic version-related risks: a meta-analysis. Obstet Gynecol 2008;112:1143–51. https://doi.org/10.1097/AOG.0b013e31818b4ade; PMid:18978117

44. Kok M, Cnossen J, Gravendeel L, van der Post J, Opmeer B, Mol BW.  Clinical factors to predict the outcome of external cephalic version: a  metaanalysis. Am J Obstet Gynecol 2008;199:630.e1–7; discussion e1–5.

45. Altisent C, Martorell M, Vidal F, S anchez MA, Parra R. The optimal mode of delivery for the haemophilia carrier expecting an affected infant: further considerations. Haemophilia 2011; 17: 818–9. https://doi.org/10.1111/j.1365-2516.2011.02505.x

46. Ljung R. The optimal mode of delivery for the haemophilia carrier expecting an affected infant is vaginal delivery.  Haemophilia 2010;16:415–9. PMid:19925629

47. Madan B, Street AM. What is the optimal mode of delivery for  the haemophilia carrier expecting an affected infant-vaginal  delivery or caesarean delivery Haemophilia 2010; 16: 425–6. https://doi.org/10.1111/j.1365-2516.2010.02238.x; PMid:20536994

48. James AH, Hoots K. The optimal mode of delivery for the haemophilia carrier expecting an affected infant is caesarean delivery. Haemophilia 2010;16:420–4. PMid:20028425

49. Ljung R, Lindgren AC, Petrini P, Tengborn L. Normal vaginal delivery is to be recommended for hemophilia carrier gravidae. Acta Paediatr 1994; 83:609–11. https://doi.org/10.1111/j.1651-2227.1994.tb13090.x; PMid:7919757

50. Nazir HF, Al Lawati T, Beshlawi I, AlSharidah S, Elshinawy M,  Alkasim F, et al. Mode of delivery and risk of intracranial haemorrhage in newborns with severe haemophilia A: a multicentre study in Gulf region. Haemophilia 2016;22:e134–8. https://doi.org/10.1111/hae.12842; PMid:26561042

51. Kletzel M, Miller CH, Becton DL, Chadduck WM, Elser JM. Postdelivery head bleeding in hemophilic neonates. Causes and management. Am J Dis Child 1989;143:1107–10. https://doi.org/10.1001/archpedi.1989.02150210143035; PMid:2773889

52. Kadir RA, Economides DL, Braithwaite J, Goldman E, Lee CA. The obstetric experience of carriers of haemophilia. Br J Obstet Gynaecol 1997;104:803–10. https://doi.org/10.1111/j.1471-0528.1997.tb12024.x

53. Royal College of Obstetricians and Gynaecologists. Caesarean Section. Consent Advice No. 7. London: RCOG; 2009.

54. Marshall NE, Fu R, Guise JM. Impact of multiple cesarean deliveries on maternal morbidity: a systematic review. Am J Obstet Gynecol 2011; 205: 262.e1–8. https://doi.org/10.1016/j.ajog.2011.06.035; PMid:22071057

55. Hansen AK, Wisborg K, Uldbjerg N, Henriksen TB. Risk of respiratory morbidity in term infants delivered by elective caesarean section: cohort study. BMJ 2008; 336: 85–7. https://doi.org/10.1136/bmj.39405.539282.BE; PMid:18077440 PMCid:PMC2190264

56. Morrison JJ, Rennie JM, Milton PJ. Neonatal respiratory morbidity and mode of delivery at term: influence of timing of elective caesarean section. Br J Obstet Gynaecol 1995;102: 101–6. https://doi.org/10.1111/j.1471-0528.1995.tb09060.x; PMid:7756199

57. Smith GC, Wood AM, White IR, Pell JP, Cameron AD, Dobbie R. Neonatal respiratory morbidity at term and the risk of childhood asthma. Arch Dis Child 2004;89:956–60. https://doi.org/10.1136/adc.2003.045971; PMid:15383441 PMCid:PMC1719687

58. Boulvain M, Marcoux S, Bureau M, Fortier M, Fraser W. Risks of induction of labour in uncomplicated term pregnancies. Paediatr Perinat Epidemiol 2001;15:131–8. https://doi.org/10.1046/j.1365-3016.2001.00337.x; PMid:11383577

59. Arrowsmith S, Wray S, Quenby S. Maternal obesity and labour complications following induction of labour in prolonged pregnancy. BJOG 2011; 118: 578–88. https://doi.org/10.1111/j.1471-0528.2010.02889.x; PMid:21265999 PMCid:PMC3085126

60. Modanlou H, Smith E, Paul RH, Hon EH. Complications of fetal blood sampling during labor. The pediatrician should always be informed when scalp samples have been taken. Clin Pediatr (Phila) 1973;12:603–6. https://doi.org/10.1177/000992287301201109

61. Sabir H, Stannigel H, Schwarz A, Hoehn T. Perinatal hemorrhagic shock after fetal scalp blood sampling. Obstet Gynecol 2010;115:419–20. https://doi.org/10.1097/AOG.0b013e3181c51aeb; PMid:20093865

62. Cheng YW, Hopkins LM, Caughey AB. How long is too long: does a prolonged second stage of labor in nulliparous women affect maternal and neonatal outcomes  Am J Obstet Gynecol 2004;191:933–8. https://doi.org/10.1016/j.ajog.2004.05.044; PMid:15467567

63. Gilad O, Merlob P, Stahl B, Klinger G. Outcome following tranexamic acid exposure during breastfeeding. Breastfeed Med 2014; 9: 407–10. https://doi.org/10.1089/bfm.2014.0027; PMid:25025926

64. Cook TM, Counsell D, Wildsmith JA; Royal College of Anaesthetists Third National Audit Project. Major complications of central neuraxial block: report on the Third National Audit Project of the Royal College of Anaesthetists. Br J Anaesth 2009;102:179–90. https://doi.org/10.1093/bja/aen360; PMid:19139027

65. Ruppen W, Derry S, McQuay HJ, Moore RA. Incidence of epidural haematoma and neurological injury in cardiovascular patients with epidural analgesia/anaesthesia: systematic review and meta-analysis. BMC Anesthesiol 2006;6:10. https://doi.org/10.1186/1471-2253-6-10; PMid:16968537 PMCid:PMC1586186

66. Choi S, Brull R. Neuraxial techniques in obstetric and non- obstetric patients with common bleeding diatheses. Anesth Analg 2009;109:648–60. https://doi.org/10.1213/ane.0b013e3181ac13d1; PMid:19608843

67. Working Party; Association of Anaesthetists of Great Britain & Ireland; Obstetric Anaesthetists’ Association; Regional Anaesthesia UK. Regional anaesthesia and patients with abnormalities of coagulation: the Association of Anaesthetists of Great Britain & Ireland, The Obstetric Anaesthetists’ Association, Regional Anaesthesia UK. Anaesthesia 2013;68:966–72. https://doi.org/10.1111/anae.12359; PMid:23905877

68. Evans D, Shaw A. Safety of intramuscular injection of hepatitis B vaccine in haemophiliacs. Br Med J 1990; 300: 1694–5. https://doi.org/10.1136/bmj.300.6741.1694-a

69. Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for preventing postpartum haemorrhage. Cochrane Database Syst Rev 2015; (6): CD007872. https://doi.org/10.1002/14651858.CD007872.pub3

70. Sentilhes L, Lasocki S, Ducloy-Bouthors AS, Deruelle P, Dreyfus M, Perrotin F, et al. Tranexamic acid for the prevention and treatment of postpartum haemorrhage. Br J Anaesth 2015; 114: 576–87. https://doi.org/10.1093/bja/aeu448; PMid:25571934

71. Peitsidis P, Kadir RA. Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opin Pharmacother 2011;12:503–16. https://doi.org/10.1517/14656566.2011.545818; PMid:21294602

72. Stoof SC, van Steenbergen HW, Zwagemaker A, Sanders YV, Cannegieter SC, Duvekot JJ, et al. Primary postpartum  haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey. Haemophilia 2015;21:505–12. https://doi.org/10.1111/hae.12635; PMid:25688733

73. Royal College of Obstetricians and Gynaecologists. Prevention and Management of Postpartum Haemorrhage. Green-top Guideline No. 52. London: RCOG; 2009.

74. Chi C, Shiltagh N, Kingman CE, Economides DL, Lee CA, Kadir RA. Identification and management of women with inherited bleeding disorders: a survey of obstetricians and gynaecologists in the United Kingdom. Haemophilia 2006;12:405–12. https://doi.org/10.1111/j.1365-2516.2006.01282.x; PMid:16834742

75. Chi C, Bapir M, Lee CA, Kadir RA. Puerperal loss (lochia) in women with or without inherited bleeding disorders. Am J Obstet Gynecol 2010;203:56.e1–5. https://doi.org/10.1016/j.ajog.2010.02.042; PMid:20417483

76. Andrew M, Paes B, Milner R, Johnston M, Mitchell L, Tollefsen DM, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988;72:1651–7. PMid:3179444

77. Kulkarni R, Lusher J. Perinatal management of newborns with haemophilia. Br J Haematol 2001;112:264–74. https://doi.org/10.1046/j.1365-2141.2001.02362.x; PMid:11167818

78. Jшrgensen FS, Felding P, Vinther S, Andersen GE. Vitamin K to neonates. Peroral versus intramuscular administration. Acta Paediatr Scand 1991; 80: 304–7. https://doi.org/10.1111/j.1651-2227.1991.tb11853.x

79. Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000;84:160–74. PMid:10959685

80. Ng C, Motto DG, Di Paola J. Diagnostic approach to von Willebrand disease. Blood 2015;125:2029–37. https://doi.org/10.1182/blood-2014-08-528398; PMid:25712990 PMCid:PMC4375103

81. Laffan MA, Lester W, O’Donnell JS, Will A, Tait RC, Goodeve A, et al. The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol 2014; 167:453–65. https://doi.org/10.1111/bjh.13064; PMid:25113304 PMCid:PMC4283483

82. Eikenboom J, Van Marion V, Putter H, Goodeve A, Rodeghiero F, Castaman G, et al. Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost 2006;4:774–82. https://doi.org/10.1111/j.1538-7836.2006.01823.x; PMid:16634746

83. James PD, Paterson AD, Notley C, Cameron C, Hegadorn C, Tinlin S, et al. Genetic linkage and association analysis in type 1 von Willebrand disease: results from the Canadian type 1 VWD study. J Thromb Haemost 2006; 4: 783–92. https://doi.org/10.1111/j.1538-7836.2006.01860.x; PMid:16634747

84. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007; 109: 112–21. Erratum 2008; 111: 3299–300. https://doi.org/10.1182/blood-2006-05-020784; PMid:16985174

85. Ranger A, Manning RA, Lyall H, Laffan MA, Millar CM. Pregnancy in type 2B VWD: a case series. Haemophilia 2012;18:406–12. https://doi.org/10.1111/j.1365-2516.2011.02691.x; PMid:22077376

86. Biguzzi E, Siboni SM, Ossola MW, Zaina B, Migliorini AC, Peyvandi F.  Management of pregnancy in type 2B von Willebrand disease: case  report and literature overview. Haemophilia 2015;21:e98–103. https://doi.org/10.1111/hae.12580; PMid:25431025

87. Kasatkar P, Shetty S, Ghosh K. Prenatal diagnosis in severe von Willebrand disease families from India using combination of  phenotypic and genotypic assays. Prenat Diagn 2014; 34: 377–81. https://doi.org/10.1002/pd.4315; PMid:24390653

88. Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW.  Haemostasis in normal pregnancy. Thromb Haemost 1984;52:176–82. PMid:6084322

89. Ramasahoye BH, Davies SV, Dasani H, Pearson JF. Obstetric management in von Willebrand’s disease: a report of 24 pregnancies  and a review of the literature. Haemophilia 1995;1:140–4. https://doi.org/10.1111/j.1365-2516.1995.tb00056.x; PMid:27214325

90. Conti M, Mari D, Conti E, Muggiasca ML, Mannucci PM. Pregnancy in women with different types of von Willebrand  disease. Obstet Gynecol 1986; 68: 282–5. PMid:3090493

91. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. Pregnancy in women with von Willebrand’s disease or factor XI deficiency. Br J Obstet Gynaecol 1998;105:314–21. https://doi.org/10.1111/j.1471-0528.1998.tb10093.x; PMid:9532993

92. Huq FY, Kulkarni A, Agbim EC, Riddell A, Tuddenham E, Kadir RA. Changes in the levels of factor VIII and von Willebrand factor in the puerperium. Haemophilia 2012;18:241–5. https://doi.org/10.1111/j.1365-2516.2011.02625.x; PMid:21951573

93. S anchez-Luceros A, Meschengieser SS, Marchese C, Votta R, Casais P, Woods AI, et al. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis 2003;14:647–51. https://doi.org/10.1097/00001721-200310000-00005; PMid:14517489

94. Mahieu B, Jacobs N, Mahieu S, Naelaerts K, Vertessen F, Weyler J, et al. Haemostatic changes and acquired activated protein C resistance in normal pregnancy. Blood Coagul Fibrinolysis 2007;18:685–8. https://doi.org/10.1097/MBC.0b013e3282f09835; PMid:17890957

95. KjellbergU, AnderssonNE, Ros enS, TengbornL,HellgrenM. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis 2003;14: 647–51. https://doi.org/10.1097/00001721-200310000-00005

96. James AH, Jamison MG. Bleeding events and other complications during pregnancy and childbirth in women with von Willebrand disease. J Thromb Haemost 2007;5:1165–9. https://doi.org/10.1111/j.1538-7836.2007.02563.x; PMid:17403089

97. Andrew M, Paes B, Milner R, Johnson M, Mitchell L, Tollefsen DM, et al. Development of the human coagulation system in the full- term infant. Blood 1987;70:165–72. PMid:3593964

98. Labarque V, Stain AM, Blanchette V, Kahr WH, Carcao MD. Intracranial haemorrhage in von Willebrand disease: a report of six cases. Haemophilia 2013; 19: 602–6. https://doi.org/10.1111/hae.12142; PMid:23556472

99. Chalmers E, Alamelu J, Collins P, Mathias M, Payne J, Richards M, et al. on behalf of the Paediatric and Rare Disorders Working Parties of UKHCDO. Intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003–2013. J Thromb Haemost 2015;13 Suppl 2:243.

100. Sanders YV, Giezenaar MA, Laros-van Gorkom BA, Meijer K, van der Bom JG, Cnossen MH, et al.; WiN study group. von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost 2014;12:1066–75. https://doi.org/10.1111/jth.12586; PMid:24750783

101. Rodegheiro F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, et al.; ISTH/SSC joint VWF and Perinatal /Pediatric Hemostasis Subcommittees Working Group. ISTH/SSC bleeding assessment tool: a standardised questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 2010; 8: 2063–5. https://doi.org/10.1111/jth.12586; PMid:24750783

102. Rydz N, James PD. The evolution and value of bleeding assessment tools. J Thromb Haemost 2012; 10: 2223–9. https://doi.org/10.1111/j.1538-7836.2012.04923.x; PMid:22974079 PMCid:PMC3893309

103. Chen YC, Chao TY, Cheng SN, Hu SH, Lius JY. Prevalence of von Willebrand disease in women with iron deficiency anaemia and menorrhagia in Taiwan. Haemophilia 2008;14:768–74. https://doi.org/10.1111/j.1365-2516.2008.01777.x; PMid:18498402

104. Rae C, Furlong W, Horsman J, Pullenayegum E, Demers C, St-Louis J, et al. Bleeding disorders, menorrhagia and iron deficiency: impacts on health-related quality of life. Haemophilia 2013;19:385–91. https://doi.org/10.1111/hae.12014; PMid:22994803 PMCid:PMC4171051

105. Leone G, Moneta E, Paparatti G, Boni P. Letter: Von Willebrand’s disease in pregnancy. N Engl J Med 1975;293:456. https://doi.org/10.1056/NEJM197508282930918; PMid:1080256

106. Castaman G, Tosetto A, Rodeghiero F. Pregnancy and delivery in women with von Willebrand’s disease and different von Willebrand factor mutations. Haematologica 2010;95:963–9. https://doi.org/10.3324/haematol.2009.011239; PMid:19951969 PMCid:PMC2878795

107. Ray JG. DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet Gynecol Surv 1998;53:450–5. https://doi.org/10.1097/00006254-199807000-00025; PMid:9662731

108. Rodeghiero F, Castaman G, Di Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand’s disease and hemophilia A. Blood 1989;74: 1997–2000. PMid:2804344

109. Castaman G, Rodeghiero F, Tosetto A, Cappelletti A, Baudo F, Eikenboom JC, et al. Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2006;4:2164–9. https://doi.org/10.1111/j.1538-7836.2006.02070.x; PMid:16999850

110. Holmberg L, Nilsson IM, Borge L, Gunnarson M, Sjo€rin E. Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand’s disease. N Engl J Med 1983;309:816–21. https://doi.org/10.1056/NEJM198310063091402; PMid:6412139

111. Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 1988;318:121. https://doi.org/10.1056/NEJM198801143180215

112. Bymes JJ, Lacarda A, Moake JL. Thrombosis following desmopressin for uremic bleeding. Am J Hematol 1988;28:63–5. https://doi.org/10.1002/ajh.2830280115

113. Mannucci PM, Bettega D, Cattaneo M. Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 1992;82:87–93. https://doi.org/10.1111/j.1365-2141.1992.tb04598.x; PMid:1419807

114. Goudemand J, Negrier C, Ounnoughene N, Sultan Y. Clinical management of patients with von Willebrand’s disease with a VHP VWF concentrate: the French experience. Haemophilia 1998;4 Suppl 3:48–52. https://doi.org/10.1046/j.1365-2516.1998.0040s3048.x

115. Borel-Derlon A, Federici AB, Roussel-Robert V, Goudemand J, Lee CA, Scharrer I, et al. Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost 2007;5:1115–24. https://doi.org/10.1111/j.1538-7836.2007.02562.x; PMid:17403090

116. Federici AB, Mannucci PM, Castaman G, Baronciani L, Bucciarelli P, Canciani MT, et al. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009; 113: 526–34. https://doi.org/10.1182/blood-2008-04-152280; PMid:18805962

117. Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008;14:171–232. https://doi.org/10.1111/j.1365-2516.2007.01643.x; PMid:18315614

118. Chi C, Lee CA, England A, Hingorani J, Paintsil J, Kadir RA. Obstetric analgesia and anaesthesia in women with inherited bleeding disorders. Thromb Haemost 2009; 101: 1104–11. https://doi.org/10.1160/TH08-10-0694

119. Silwer J. von Willebrand’s disease in Sweden. Acta Paediatr Scand Suppl 1973;238:1–159. PMid:4550005

120. Cyklo-f 500 mg film coated tablets [www.medicines.org.uk/emc/ medicine/27753]. Accessed 2015 Oct 7.

121. Faculty of Sexual and Reproductive Healthcare. Clinical Guidance. Contraception After Pregnancy. London: FSRH; 2017.

122. Mannucci PM, Duga S, Peyvandi F. Recessively inherited coagulation disorders. Blood 2004;104:1243–52. https://doi.org/10.1182/blood-2004-02-0595; PMid:15138162

123. Mumford AD, Ackroyd S, Alikhan R, Bowles L, Chowdary P, Grainger J, et al.; BCSH Committee. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors’ Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014;167:304–26. https://doi.org/10.1111/bjh.13058; PMid:25100430

124. Peyvandi F, Duga S, Akhavan S, Mannucci PM. Rare coagulation deficiencies. Haemophilia 2002;8:308–21. https://doi.org/10.1046/j.1365-2516.2002.00633.x; PMid:12010428

125. Seligsohn U. Factor XI deficiency. Thromb Haemost 1993;70:68–71.  PMid:8236117

126. Seligsohn U. High gene frequency of factor XI (PTA) deficiency  in Ashkenazi Jews. Blood 1978; 51: 1223–8. PMid:647126

127. Shpilberg O, Peretz H, Zivelin A, Yatuv R, Chetrit A, Kulka T,  et al. One of the two common mutations causing factor XI deficiency in Ashkenazi Jews (type II) is also prevalent in Iraqi Jews, who represent the ancient gene pool of Jews. Blood 1995;85:429–32.  PMid:7811996

128. Tavori S, Brenner B, Tatarsky I. The effect of combined factor XI deficiency with von Willebrand factor abnormalities on haemorrhagic diathesis. Thromb Haemost 1990;63:36–8. PMid:2111046

129. Bolton-Maggs PH, Patterson DA, Wensley RT, Tuddenham EG. Definition of the bleeding tendency in factor XI-deficient kindreds—a clinical and laboratory study. Thromb Haemost 1995; 73: 194–202. PMid:7792729

130. Von dem Borne PA, Bajzar L, Meijers JC, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323–7. https://doi.org/10.1172/JCI119412; PMid:9153272 PMCid:PMC508069

131. Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012;10:615–21. https://doi.org/10.1111/j.1538-7836.2012.04844.x; https://doi.org/10.1111/j.1538-7836.2012.04653.x; PMid:22321862

132. Salomon O, Steinberg DM, Seligshon U. Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 2006;12:490–3. https://doi.org/10.1111/j.1365-2516.2006.01304.x; PMid:16919078

133. Bolton-Maggs PH, Young Wan-Yin B, McCraw AH, Slack J, Kernoff PB. Inheritance and bleeding in factor XI deficiency. Br J Haematol 1988;69:521–8. https://doi.org/10.1111/j.1365-2141.1988.tb02409.x; PMid:3408688

134. Bolton-Maggs PH. Factor XI deficiency–resolving the enigma  Hematology Am Soc Hematol Educ Program 2009;1:97–105. https://doi.org/10.1182/asheducation-2009.1.97

135. Hellgren M, Blomback M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. Gynecol Obstet Invest 1981;12:141–54. https://doi.org/10.1159/000299596; PMid:7239349

136. Myers B, Pavord S, Kean L, Hill M, Dolan G. Pregnancy outcome in Factor XI deficiency: incidence of miscarriage, antenatal and postnatal haemorrhage in 33 women with Factor XI deficiency. BJOG 2007;114:643–6. https://doi.org/10.1111/j.1471-0528.2007.01296.x; PMid:17439571

137. Salomon O, Steinberg DM, Tamarin I, Zivelin A, Seligsohn U. Plasma replacement therapy during labor is not mandatory for women with severe factor XI deficiency. Blood Coagul Fibrinolysis 2005;16:37–41. https://doi.org/10.1097/00001721-200501000-00006; PMid:15650544

138. Chi C, Kulkarni A, Lee CA, Kadir RA. The obstetric experience of women with factor XI deficiency. Acta Obstet Gynecol Scand 2009;88:1095–100. https://doi.org/10.1080/00016340903144238; PMid:19685354

139. Myers B, Neal R, Curry N, Kadir R, Pavord S. Blood group, bleeding phenotype and post-partum haemorrhage in factor XI-deficient women. International Society on Thrombosis and Haemostasis 2015 Congress, 20–25 June 2015, Toronto, Canada. Poster 175.

140. Bolton-Maggs PH, Colvin BT, Satchi G, Lee CA, Lucas GS. Thrombogenic potential of factor XI concentrate. Lancet 1994;344:748–9. https://doi.org/10.1016/S0140-6736(94)92237-3

141. Mannucci PM, Bauer KA, Santagostino E, Faioni E, Barzegar S, Coppola R, et al. Activation of the coagulation cascade after infusion of a factor XI concentrate in congenitally deficient patients. Blood 1994;84:1314–9. PMid:8049446

142. Bolton-Maggs P, Goudemand J, Hermans C, Makris M, de Moerloose P. FXI concentrate use and the risk of thrombosis. Haemophilia 2014; 20:e349–51. https://doi.org/10.1111/hae.12457; PMid:24785157

143. Riddell A, Abdul-Kadir R, Pollard D, Tuddenham E, Gomez K. Monitoring low dose recombinant factor VIIa therapy in patients with severe factor XI deficiency undergoing surgery. Thromb Haemost 2011;106:521–7. https://doi.org/10.1160/TH10-12-0816; PMid:21833443

144. Salomon O, Zivelin A, Livnat T, Dardik R, Loewenthal R, Avishai O, et al. Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency. Blood 2003;101:4783–8. https://doi.org/10.1182/blood-2002-09-2794; PMid:12586617

145. Livnat T, Tamarin I, Mor Y, Winckler H, Horowitz Z, Korianski Y, et al. Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI- deficient patients with inhibitor antibodies. Thromb Haemost 2009; 102:487–92. https://doi.org/10.1160/TH09-03-0172

146. Ginsberg SS, Clyne LP, McPhedran P, Duffy TP, Hanson T. Successful childbirth by a patient with congenital factor XI deficiency and an acquired inhibitor. Br J Haematol 1993;84: 172–4. https://doi.org/10.1111/j.1365-2141.1993.tb03044.x; PMid:8338772

147. Bolton–Maggs PH. Treatment of Hemophilia: Factor XI deficiency and its management. 3rd ed. Montr eal, Qu ebec: World Federation of Hemophilia; 2008 [www.exodontia.info/files/Trea tment_of_H_mophilia_2008._Factor_XI_Deficiency_Its_Mana gement.pdf]. Accessed 2016 Jul 26.

148. O’Connell NM, Pascoe GM, Riddell AR, Brown SA, Perry DJ, Lee CA. Prevention of surgical bleeding with recombinant factor VIIa in patients with factor XI deficiency. Blood 2002; 100: 697a.

149. Lee CA, Chi C, Pavord SR, Bolton-Maggs PH, Pollard DA, Hinchcliffe-Wood A, et al. The obstetric and gynaecological management of women with inherited bleeding disorders review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors’ Organization. Haemophilia 2006; 12: 301–36. https://doi.org/10.1111/j.1365-2516.2006.01314.x; PMid:16834731

150. Singh A, Harnett MJ, Connors JM, Camann WR. Factor XI deficiency and obstetrical anesthesia. Anesth Analg 2009;108:1882–5. https://doi.org/10.1213/ane.0b013e3181a28715; PMid:19448217

151. Reuveni A, Orbach-Zinger S, Eidelman LA, Ginosar Y, Ioscovich A.  Peripartum anesthetic management of patients with Factor XI  deficiency. J Perinat Med 2013;42:295–300.

152. Bolton-Maggs PH, Perry DJ, Chalmers EA, Parapia LA, Wilde JT,  Williams MD, et al. The rare coagulation disorders—review with guidelines for management from the United Kingdom Haemophilia Centre Doctors’ Organisation. Haemophilia 2004; 10: 593–628. https://doi.org/10.1111/j.1365-2516.2004.00944.x; PMid:15357789

153. Herrmann FH, Auerswald G, Ruiz-Saez A, Navarrete M, Pollmann H, Lopaciuk S, et al.; Greifswald Factor X Deficiency Study Group. Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia 2006;12:479–89. https://doi.org/10.1111/j.1365-2516.2006.01303.x; PMid:16919077

154. Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood 2015;125:2052–61. https://doi.org/10.1182/blood-2014-08-532820; PMid:25712993

155. Acharya SS, Coughlin A, Dimichele DM; North American Rare Bleeding Disorder Study Group. Rare Bleeding Disorder Registry: deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2004;2:248–56. https://doi.org/10.1111/j.1538-7836.2003.t01-1-00553.x; PMid:14995986

156. Ivaskevicius V, Biswas A, Bevans C, Schroeder V, Kohler HP, Rott H, et al. Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. Haematologica 2010;95:956–62. https://doi.org/10.3324/haematol.2009.017210; PMid:20179087 PMCid:PMC2878794

157. Kulkarni AA, Lee CA, Kadir RA. Pregnancy in women with congenital factor VII deficiency. Haemophilia 2006; 12: 413–6. https://doi.org/10.1111/j.1365-2516.2006.01219.x; https://doi.org/10.1111/j.1365-2516.2006.01287.x; PMid:16834743

158. Konje JC, Murphy P, de Chazal R, Davidson A, Taylor D. Severe factor X deficiency and successful pregnancy. Br J Obstet Gynaecol 1994;101:910–1. https://doi.org/10.1111/j.1471-0528.1994.tb13557.x

159. Condie RG. A serial study of coagulation factors XII, XI and X in plasma in normal pregnancy and in pregnancy complicated by pre-eclampsia. Br J Obstet Gynaecol 1976;83:636–9. https://doi.org/10.1111/j.1471-0528.1976.tb00902.x; PMid:952795

160. Sharief LA, Kadir RA. Congenital factor XIII deficiency in women: a systematic review of literature. Haemophilia 2013;19: e349–57. https://doi.org/10.1111/hae.12259; PMid:23992439

161. Tran HT, Sшrensen B, Rea CJ, Bjшrnsen S, Ueland T, Pripp AH, et al. Tranexamic acid as adjunct therapy to bypassing agents in haemophilia A patients with inhibitors. Haemophilia 2014;20: 369–75. https://doi.org/10.1111/hae.12318; PMid:24251535

162. Mariani G, Herrmann FH, Dolce A, Batorova A, Etro D, Peyvandi F, et al.; International Factor VII Deficiency Study Group. Clinical phenotypes and factor VII genotype in congenital factor VII deficiency. Thromb Haemost 2005; 93: 481–7. PMid:15735798

163. Catanzarite VA, Novotny WF, Cousins LM, Schneider JM. Pregnancies in a patient with congenital absence of prothrombin activity: case report. Am J Perinatol 1997;14:135–8. https://doi.org/10.1055/s-2007-994113; PMid:9259914

164. Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost 1999;82:1207–14. PMid:10544899

165. Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol 1998;103:1067–9. https://doi.org/10.1046/j.1365-2141.1998.01077.x; PMid:9886321

166. Noia G, De Carolis S, De Stefano V, Ferrazzani S, De Santis L, Carducci B, et al. Factor V deficiency in pregnancy complicated by Rh immunization and placenta previa. A case report and review of the literature. Acta Obstet Gynecol Scand 1997;76:890–2. https://doi.org/10.3109/00016349709024374; PMid:9351421

167. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14: 671–84. https://doi.org/10.1111/j.1365-2516.2008.01695.x

168. Girolami A, Scandellari R, Lombardi AM, Girolami B, Bortoletto E, Zanon E. Pregnancy and oral contraceptives in factor V deficiency: a study of 22 patients (five homozygotes and 17 heterozygotes) and review of the literature. Haemophilia 2005;11:26–30. https://doi.org/10.1111/j.1365-2516.2005.01056.x; PMid:15660985

169. Coppola A, Maruotti GM, Feola G, Catalano A, Quaglia F, Tomaiuolo M, et al. Management of patients with factor V deficiency: open issues from the challenging history of a woman with anaphylactic transfusion reactions. Haemophilia 2010;16: 560–3. PMid:20028426

170. Di Paola J, Nugent D, Young G. Current therapy for rare factor deficiencies. Haemophilia 2001;7 Suppl 1: 16–22. https://doi.org/10.1046/j.1365-2516.2001.00100.x

171. Herrmann FH, Wulff K, Auerswald G, Schulman S, Astermark J, Batorova A, et al.; Greifswald Factor FVII Deficiency Study Group. Factor VII deficiency: clinical manifestation of 717 subjects from Europe and Latin America with mutations in the factor 7 gene. Haemophilia 2009;15:267–80. https://doi.org/10.1111/j.1365-2516.2008.01910.x; PMid:18976247

172. Bernardi F, Dolce A, Pinotti M, Shapiro AD, Santagostino E, Peyvandi F, et al.; International Factor VII Deficiency Study Group. Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost 2009;7:774–9. https://doi.org/10.1111/j.1538-7836.2009.03329.x; PMid:19245420

173. Di Minno MN, Dolce A, Mariani G; STER Study Group. Bleeding symptoms at disease presentation and prediction of ensuing bleeding in inherited FVII deficiency. Thromb Haemost 2013; 109: 1051–9. https://doi.org/10.1160/TH12-10-0740; PMid:23571462

174. Fadel HE, Krauss JS. Factor VII deficiency and pregnancy. Obstet Gynecol 1989;73:453–4. https://doi.org/10.1016/0020-7292(89)90244-0

175. Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. Haemophilia 2009;15:990–1005. https://doi.org/10.1111/j.1365-2516.2009.01984.x; PMid:19298378

176. Baumann Kreuziger LM, Morton CT, Reding MT. Is prophylaxis required for delivery in women with factor VII deficiency  Haemophilia 2013;19:827–32. https://doi.org/10.1111/hae.12167; PMid:23607277 PMCid:PMC3769463

177. Girolami A, Randi ML, Ruzzon E, Lombardi AM, Girolami B, Fabris F. Pregnancy and oral contraceptives in congenital bleeding disorders of the vitamin K-dependent coagulation factors. Acta Haematol 2006;115:58–63. https://doi.org/10.1159/000089467; PMid:16424651

178. Nance D, Josephson NC, Paulyson-Nunez K, James AH. Factor X deficiency and pregnancy: preconception counselling and therapeutic options. Haemophilia 2012; 18: e277–85. https://doi.org/10.1111/j.1365-2516.2011.02724.x; PMid:22151249

179. Kumar M, Mehta P. Congenital coagulopathies and pregnancy: report of four pregnancies in a factor X-deficient woman. Am J Hematol 1994;46:241–4. https://doi.org/10.1002/ajh.2830460315; PMid:8192155

180. Burrows RF, Ray JG, Burrows EA. Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature. Obstet Gynecol Surv 2000; 55: 103–8. https://doi.org/10.1097/00006254-200002000-00024; PMid:10674253

181. Nugent D. Corifact TM/ Fibrogammin P in the prophylactic treatment of hereditary factor XIII deficiency: results of a prospective, multicenter, open-label study. Thromb Res 2012;130 Suppl 2:S12–4. https://doi.org/10.1016/S0049-3848(13)70005-7

182. Inbal A, Oldenburg J, Carcao M, Rosholm A, Tehranchi R, Nugent D. Recombinant factor XIII: a safe and novel treatment for congenital factor XIII deficiency. Blood 2012; 119: 5111–7. https://doi.org/10.1182/blood-2011-10-386045; PMid:22451421

183. Asahina T, Kobayashi T, Takeuchi K, Kanayama N. Congenital blood coagulation factor XIII deficiency and successful deliveries: a review of the literature. Obstet Gynecol Surv 2007;62:255–60. https://doi.org/10.1097/01.ogx.0000259176.03156.2b; PMid:17371605

184. Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol 1999; 107: 468–84. https://doi.org/10.1046/j.1365-2141.1999.01648.x; PMid:10583246

185. Mannucci PM. Bleeding symptoms in heterozygous factor XIII [corrected] deficiency. Haematologica 2010;95:e6. https://doi.org/10.3324/haematol.2010.028969; PMid:20807981 PMCid:PMC2930978

186. Seligsohn U, Zivelin A, Zwang E. Combined factor V and factor VIII deficiency among non-Ashkenazi Jews. N Engl J Med 1982;307:1191–5. https://doi.org/10.1056/NEJM198211043071907; PMid:6811896

187. Peyvandi F, Tuddenham EG, Akhtari AM, Lak M, Mannucci PM. Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII. Br J Haematol 1998;100:773–6. https://doi.org/10.1046/j.1365-2141.1998.00620.x; PMid:9531348

188. Oukkache B, El Graoui O, Zafad S. Combined factor V and VIII deficiency and pregnancy. Int J Hematol 2012; 96: 786–8. https://doi.org/10.1007/s12185-012-1201-z; PMid:23073620

189. Lak M, Keihani M, Elahi F, Peyvandi F, Mannucci PM. Bleeding and thrombosis in 55 patients with inherited afibrinogenaemia. Br J Haematol 1999; 107: 204–6. https://doi.org/10.1046/j.1365-2141.1999.01681.x; PMid:10520042

190. Peyvandi F, Haertel S, Knaub S, Mannucci PM. Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia. J Thromb Haemost 2006; 4: 1634–7. https://doi.org/10.1111/j.1538-7836.2006.02014.x; PMid:16839371

191. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995;73:151–61.  PMid:7740487

192. Miesbach W, Scharrer I, Henschen A, Neerman-Arbez M, Spitzer S, Galanakis D. Inherited dysfibrinogenemia: clinical phenotypes associated with five different fibrinogen structure defects. Blood Coagul Fibrinolysis 2010;21:35–40.  https://doi.org/10.1097/MBC.0b013e328331e6db; PMid:19923982

193. de Moerloose P, Casini A, Neerman-Arbez M. Congenital fibrinogen disorders: an update. Semin Thromb Hemost 2013;39:585–95. https://doi.org/10.1055/s-0033-1349222; PMid:23852822

194. Shapiro SE, Phillips E, Manning RA, Morse CV, Murden SL, Laffan MA, et al. Clinical phenotype, laboratory features and genotype of 35 patients with heritable dysfibrinogenaemia. Br J Haematol 2013;160:220–7. https://doi.org/10.1111/bjh.12085; PMid:23061815

195. Goodwin TM. Congenital hypofibrinogenemia in pregnancy. Obstet Gynecol Surv 1989;44:157–61. https://doi.org/10.1097/00006254-198903000-00001; PMid:2652009

196. Yamanaka Y, Takeuchi K, Sugimoto M, Sato A, Nakago S, Maruo T. Dysfibrinogenemia during pregnancy treated successfully with fibrinogen. Acta Obstet Gynecol Scand 2003;82:972–3. https://doi.org/10.1034/j.1600-0412.2003.00211.x; PMid:12956852

197. Roqu e H, Stephenson C, Lee MJ, Funai EF, Popiolek D, Kim E, et al. Pregnancy-related thrombosis in a woman with congenital afibrinogenemia: a report of two successful pregnancies. Am J Hematol 2004;76:267–70. https://doi.org/10.1002/ajh.20110; PMid:15224364

198. Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco-Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. J Thromb Haemost 2011;9:1687–704. https://doi.org/10.1111/j.1538-7836.2011.04424.x; PMid:21711446

199. Mensah P, Oppenheimer C, Watson C, Pavord S. Congenital afibrinogenaemia in pregnancy. Haemophilia 2011;17:167–8. https://doi.org/10.1111/j.1365-2516.2010.02363.x; PMid:20695910

200. Munoz J, Schering J, Lambing A, Neal S, Goyert G, Green PM,  et al. The dilemma of inherited dysfibrinogenemia during pregnancy. Blood Coagul Fibrinolysis 2012;23:775–7. https://doi.org/10.1097/MBC.0b013e328358e96d; PMid:23135383

201. Franchini M, Raffaelli R, Musola M, Memmo A, Poli G, Franchi M, et al. Management of inherited dysfibrinogenemia during pregnancy: a description of four consecutive cases. Ann Hematol 2007;86:693–4. https://doi.org/10.1007/s00277-007-0307-5; PMid:17492257

202. Lo pez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998; 91: 4397–418. PMid:9616133

203. Prabu P, Parapia LA. Bernard-Soulier syndrome in pregnancy. Clin Lab Haematol 2006;28:198–201. https://doi.org/10.1111/j.1365-2257.2006.00780.x; PMid:16706937

204. Bolton-Maggs PH, Chalmers EA, Collins PW, Harrison P, Kitchen S, Leisner RJ, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006;135:603–33. https://doi.org/10.1111/j.1365-2141.2006.06343.x; PMid:17107346

205. Kunishima S, Kamiya T, Saito H. Genetic abnormalities of Bernard-Soulier syndrome. Int J Hematol 2002;76:319–27.  https://doi.org/10.1007/BF02982690; PMid:12463594

206. Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, et al. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011; 155: 30–44. https://doi.org/10.1111/j.1365-2141.2011.08793.x; PMid:21790527

207. Peitsidis P, Datta T, Pafilis I, Otomewo O, Tuddenham EG, Kadir RA. Bernard Soulier syndrome in pregnancy: a systematic review. Haemophilia 2010;16:584–91. https://doi.org/10.1111/j.1365-2516.2009.02137.x

208. Michalas S, Malamitsi-Puchner A, Tsevrenis H. Pregnancy and delivery in Bernard-Soulier syndrome. Acta Obstet Gynecol Scand 1984;63:185–6. https://doi.org/10.3109/00016348409154659; PMid:6539555

209. Heslop HE, Hickton CM, Laird E, Tait JD, Doig JR, Beard EJ. Twin pregnancy and parturition in a patient with the Bernard Soulier syndrome. Scand J Haematol 1986;37:71–3. https://doi.org/10.1111/j.1600-0609.1986.tb01774.x; PMid:3489980

210. Zafar S, Sultana S, Iqbal W, Bhatti FA, Khanam Akhtar KA, Muhammed A, et al. Pregnancy Outcome in Bernard-Soulier Syndrome Complicated by Preeclampsia. J Turk Ger Gynecol Assoc 2007;8:324–6.

211. Stroncek DF, Rebulla P. Platelet transfusions. Lancet 2007;370:427–38. https://doi.org/10.1016/S0140-6736(07)61198-2

212. Waldenstro€m E, Holmberg L, Axelsson U, Winqvist I, Nilsson IM. Bernard-Soulier syndrome in two Swedish families: effect of DDAVP on bleeding time. Eur J Haematol 1991; 46:182–7. https://doi.org/10.1111/j.1600-0609.1991.tb01274.x; PMid:1901273

213. Cattaneo M. Desmopressin in the treatment of patients with defects of platelet function. Haematologica 2002; 87: 1122–4. PMid:12414337

214. Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia 2011; 17: e 858–69.

215. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004;104:3858–64. https://doi.org/10.1182/blood-2004-06-2223; PMid:15328151

216. Coppola A, Di Minno G. Desmopressin in inherited disorders of platelet function. Haemophilia 2008; 14 Suppl 1:31–9. https://doi.org/10.1111/j.1365-2516.2007.01607.x

217. Santoro C, Rago A, Biondo F, Conti L, Pulcinelli F, Laurenti L, et al. Prevalence of allo-immunization anti-HLA and anti-integrin alphaIIbbeta3 in Glanzmann Thrombasthenia patients. Haemophilia 2010;16:805–12. https://doi.org/10.1111/j.1365-2516.2010.02230.x; PMid:20345392

218. Ghevaert C, Campbell K, Stafford P, Metcalfe P, Casbard A, Smith GA, et al. HPA-1a antibody potency and bioactivity do not predict severity of fetomaternal alloimmune thrombocytopenia. Transfusion 2007; 47:1296–305. https://doi.org/10.1111/j.1537-2995.2007.01273.x; PMid:17581167

219. Killie MK, Husebekk A, Kaplan C, Taaning E, Skogen B. Maternal human platelet antigen-1a antibody level correlates with the platelet count in the newborns: a retrospective study. Transfusion 2007; 47:55–8. https://doi.org/10.1111/j.1537-2995.2007.01063.x; PMid:17207230

220. Radder CM, Brand A, Kanhai HH. A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2001;185: 683–8. https://doi.org/10.1067/mob.2001.116727; PMid:11568798

221. Pacheco LD, Berkowitz RL, Moise KJ Jr, Bussel JB, McFarland JG, Saade GR. Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. Obstet Gynecol 2011;118:1157–63. https://doi.org/10.1097/AOG.0b013e31823403f4; PMid:22015886

222. Rayment R, Brunskill SJ, Soothill PW, Roberts DJ, Bussel JB, Murphy MF. Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane Database Syst Rev 2011; (5): CD004226. https://doi.org/10.1002/14651858.CD004226.pub3

223. Seligsohn U, Mibashan RS, Rodeck CH, Nicolaides KH, Millar DS, Coller BS. Prenatal diagnosis of Glanzmann’s thrombasthenia. Lancet 1985;28:1419. https://doi.org/10.1016/S0140-6736(85)92579-6

224. French DL, Coller BS, Usher S, Berkowitz R, Eng C, Seligsohn U, et al. Prenatal diagnosis of Glanzmann thrombasthenia using the polymorphic markers BRCA1 and THRA1 on chromosome 17. Br J Haematol 1998;102:582–7. https://doi.org/10.1046/j.1365-2141.1998.00798.x; PMid:9695977

225. Srivastava A, Usher S, Nelson EJ, Jayandharan G, Shaji RV, Chandy M, et al. Prenatal diagnosis of Glanzmann thrombasthenia. Natl Med J India 2003; 16:207–8. PMid:14606769

226. van der Lugt NM, van Kampen A, Walther FJ, Brand A, Lopriore E. Outcome and management in neonatal thrombocytopenia due to maternal idiopathic thrombocytopenic purpura. Vox Sang 2013;105:236–43. PMid:23782272

227. Alamelu J, Liesner R. Modern management of severe platelet function disorders. Br J Haematol 2010; 149: 813–23. https://doi.org/10.1111/j.1365-2141.2010.08191.x; PMid:20456364

228. Devaney SA, Palomaki GE, Scott JA, Bianchi DW. Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-analysis. JAMA 2011;306:627–36. https://doi.org/10.1001/jama.2011.1114; PMid:21828326 PMCid:PMC4526182

229. Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM, et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet 1998;62:768–75. https://doi.org/10.1086/301800; PMid:9529358 PMCid:PMC1377040

230. Hill M, Finning K, Martin P, Hogg J, Meaney C, Norbury G, et al. Non-invasive prenatal determination of fetal sex: translating research into clinical practice. Clin Genet 2011;80:68–75. https://doi.org/10.1111/j.1399-0004.2010.01533.x; PMid:20840219

231. Cutler J, Chappell LC, Kyle P, Madan B. Third trimester amniocentesis for diagnosis of inherited bleeding disorders prior to delivery. Haemophilia 2013;19:904–7. https://doi.org/10.1111/hae.12247; PMid:23919291

232. Keeney S, Sempasa B, Sutherland M, Cumming A, Hay C, Nash M, et al. Management of delivery options informed by third trimester amniocentesis for inherited bleeding disorders – a single centre experience. Br J Haematol 2014;165 Suppl 1:45. Abstract 103.

233. Geraedts G, De Wert GM. Preimplantation genetic diagnosis. Clin Genet 2009; 76:315–25. https://doi.org/10.1111/j.1399-0004.2009.01273.x; PMid:19793305

234. Michaelides K, Tuddenham EG, Turner C, Lavender B, Lavery SA. Live birth following the first mutation specific pre-implantation genetic diagnosis for haemophilia A. Thromb Haemost 2006; 95: 373–9. https://doi.org/10.1160/TH05-08-0574

235. S anchez-GarciaJF, GallardoD, NavarroJ, M arquezC,GrisJM, S anchez MA, et al. A versatile strategy for preimplantation genetic diagnosis of haemophilia A based on F8-gene sequencing. Thromb Haemost 2006; 96:839–45. https://doi.org/10.1160/TH06-05-069

236. Lavery S. Preimplantation genetic diagnosis of haemophilia. Br J Haematol 2009;144:303–7. https://doi.org/10.1111/j.1365-2141.2008.07391.x; PMid:19036080

237. Laurie AD, Hill AM, Harraway JR, Fellowes AP, Phillipson GT, Benny PS, et al. Preimplantation genetic diagnosis for hemophilia A using indirect linkage analysis and direct genotyping approaches. J Thromb Haemost 2010; 8: 783–9. https://doi.org/10.1111/j.1538-7836.2010.03768.x; PMid:20102489

238. Tsui NB, Kadir RA, Chan KC, Chi C, Mellars G, Tuddenham EG, et al. Noninvasive prenatal diagnosis of haemophilia by microfluidics digital PCR analysis of maternal plasma DNA. Blood 2011; 117:3684–91. https://doi.org/10.1182/blood-2010-10-310789; PMid:21263151